David Huggins, PhD, serves as Principal of Small Molecule Drug Development at MSK Therapeutics Bridge Labs (TxBL) in the Office of Entrepreneurship & Commercialization. He provides scientific leadership for small molecule drug discovery projects, directing the selection and optimization of drug candidates. His responsibilities include overseeing the development and application of new assays, refining hits and leads, generating robust data packages for commercial partnering, and coordinating internal and external resources. He joined MSK in 2025.
Prior to joining MSK, David was the Executive Director of Computational Biomedicine at the Sanders Tri-Institutional Therapeutics Discovery Institute, where he led the computational modelling team. Previously, he served as a Group Leader at the Cavendish Physics Laboratory at the University of Cambridge.
David received his Master’s degree in Chemistry from the University of Oxford in 2002 and his PhD in Computational Chemistry from the University of Oxford in 2005.